Finch Therapeutics Group Inc
FNCH
Market Cap$21.6M
Close$
$-3.65
128.1% downside
Current Fair Value
128.1% downsideOvervalued by 128.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $21.60 Million |
|---|---|
| Enterprise Value | $34.55 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-46.59 |
| Beta | 1.25 |
| Outstanding Shares | 1,605,763 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -1.84 |
|---|---|
| PEG | 6.04 |
| Price to Sales | 13.0 |
| Price to Book Ratio | 1.63 |
| Enterprise Value to Revenue | 12.14 |
| Enterprise Value to EBIT | -1.75 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.84 |
| Debt to Equity | 2.04 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Finch Therapeutics Group Inc
131 employeesFinch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs. With the capabilities to develop both complete and ta...